Reports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2017–2020: A Review
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
An important role of modern forensic and clinical toxicologists is to monitor the adverse events of novel psychoactive substances (NPS). Following a prior review from 2013 to 2016, this critical literature review analyzes and evaluates published case reports for NPS from January 2017 through December 2020. The primary objective of this study is to assist in the assessment and interpretation of these cases as well as provide references for confirmation methods. Chemistry, pharmacology, adverse events and user profiles (e.g., polypharmacy) for NPS are provided including case history, clinical symptoms, autopsy findings and analytical results. Literature reviews were performed in PubMed and Google Scholar for publications using search terms such as NPS specific names, general terms (e.g., ‘designer drugs’ and ‘novel psychoactive substances’), drug classes (e.g., ‘designer stimulants’) and outcome-based terms (e.g., ‘overdose’ and ‘death’). Government and website drug surveillance databases and abstracts published by professional forensic science organizations were also searched. Toxicological data and detailed case information were extracted, tabulated, analyzed and organized by drug category. Case reports included overdose fatalities (378 cases), clinical treatment and hospitalization (771 cases) and driving under the influence of drugs (170 cases) for a total of 1,319 cases providing details of adverse events associated with NPS. Confirmed adverse events with associated toxidromes of more than 60 NPS were reported including synthetic cannabinoid, NPS stimulant, NPS hallucinogen, NPS benzodiazepine and NPS opioid cases. Fifty of these NPS were reported for the first time in January 2017 through December 2020 as compared to the previous 4 years surveyed. This study provides insight and context of case findings described in the literature and in digital government surveillance databases and websites during a recent 4-year period. This review will increase the awareness of adverse events associated with NPS use to better characterize international emerging drug threats.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The triple wave epidemic: Supply and demand drivers of the US opioid overdose crisis
Ciccarone, D. (2019) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2019.01.010 · Cited by 677
Designer drugs: mechanism of action and adverse effects
Luethi, D., & Liechti, M. E. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02693-7 · Cited by 262
Illicit fentanyls in the opioid street market: desired or imposed?
Mars, S. G., Rosenblum, D., & Ciccarone, D. (2019) · Addiction · doi:10.1111/add.14474 · Cited by 185
Vandeputte, M. M., Van Uytfanghe, K., Layle, N. K., St. Germaine, D. M., Iula, D. M., & Stove, C. P. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00064 · Cited by 161
Fentanyl shock: The changing geography of overdose in the United States
Zoorob, M. (2019) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2019.04.010 · Cited by 160
Isotonitazene Quantitation and Metabolite Discovery in Authentic Forensic Casework
Krotulski, A. J., Papsun, D. M., Kacinko, S. L., & Logan, B. K. (2020) · Journal of Analytical Toxicology · doi:10.1093/jat/bkaa016 · Cited by 146
Self-citationPark, J. N., Rashidi, E., Foti, K., Zoorob, M., Sherman, S., & Alexander, G. C. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.108416 · Cited by 128
Blanckaert, P., Cannaert, A., Van Uytfanghe, K., Hulpia, F., Deconinck, E., Van Calenbergh, S., & Stove, C. (2020) · Drug Testing and Analysis · doi:10.1002/dta.2738 · Cited by 116
Baumann, M. H., Majumdar, S., Le Rouzic, V., Hunkele, A., Uprety, R., Huang, X. P., Xu, J., Roth, B. L., Pan, Y.-X., & Pasternak, G. W. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.08.016 · Cited by 92
Mueller, F., Bogdal, C., Pfeiffer, B., Andrello, L., Ceschi, A., Thomas, A., & Grata, E. (2021) · Forensic Science International · doi:10.1016/j.forsciint.2021.110686 · Cited by 82
Optimization of a series of mu opioid receptor (MOR) agonists with high G protein signaling bias
Kennedy, N. M., Schmid, C. L., Ross, N. C., Lovell, K. M., Yue, Z., Chen, Y. T., Cameron, M. D., Bohn, L. M., & Bannister, T. D. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01136 · Cited by 71
Zibbell, J. E., Aldridge, A. P., Cauchon, D., DeFiore-Hyrmer, J., & Conway, K. P. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.14666 · Cited by 69
First Report on Brorphine: The Next Opioid on the Deadly New Psychoactive Substance Horizon?
Verougstraete, N., Vandeputte, M. M., Lyphout, C., Cannaert, A., Hulpia, F., Van Calenbergh, S., Verstraete, A. G., & Stove, C. (2021) · Journal of Analytical Toxicology · doi:10.1093/jat/bkaa094 · Cited by 44
The Toxicology Investigators Consortium Case Registry—the 2019 Annual Report
Spyres, M. B., Farrugia, L. A., Kang, A. M., Aldy, K., Calello, D. P., Campleman, S. L., Li, S., Beauchamp, G. A., Wiegand, T., Wax, P. M., et al. (2020) · Journal of Medical Toxicology · doi:10.1007/s13181-020-00810-7 · Cited by 34
Death associated with brorphine, an emerging novel synthetic opioid
Vohra, V., King, A. M., Jacobs, E., & Aaron, C. (2021) · Clinical Toxicology · doi:10.1080/15563650.2021.1879111 · Cited by 16
Cited by
Non-Fentanyl New Synthetic Opioids—An Update
Zawilska, J. B., Adamowicz, P., Kurpeta, M., & Wojcieszak, J. (2023) · Forensic Science International · doi:10.1016/j.forsciint.2023.111775 · Cited by 55
Vandeputte, M. M., & Stove, C. P. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110470 · Cited by 36
Ververi, C., Galletto, M., Massano, M., Alladio, E., Vincenti, M., & Salomone, A. (2024) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2024.115975 · Cited by 34
Activity-based detection of synthetic cannabinoid receptor agonists in plant materials
Timmerman, A., Balcaen, M., Coopman, V., Degreef, M., Pottie, E., & Stove, C. P. (2024) · Harm Reduction Journal · doi:10.1186/s12954-024-01044-4 · Cited by 8
“…higher potency and efficacy at CB 1 [5], and may cause serious adverse effects, including agitation [6], cardiovascular problems [7], psychological disorders [8, 9], nausea and vomiting, depressed breathing, muscle twitches, acute renal failure, suicidal ideation and cognitive impairment [10, 11].”
Background
Metadata
- Authors
- Mohr, A. L. A., Logan, B. K., Fogarty, M. F., Krotulski, A. J., Papsun, D. M., Kacinko, S. L., Huestis, M. A., & Ropero-Miller, J. D.
- Venue
- Journal of Analytical Toxicology
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-04-21
- Volume
- 46
- Issue
- 6
- Pages
- e116-e185
- ISSN
- 0146-4760 (ISSN-L)
- 1945-2403
- OpenAlex
- W4225666514
- Cited by
- 68
- References
- 15
- FWCI
- 30.68
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.